CALGB 10701: A Phase II Study of Dasatinib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy followed by Transplantation for Adults ≥ 50 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG

Study Status

Open to Enrollment

Study Description

This is a clinical trial for patients with acute lymphoblastic leukemia (ALL) with an abnormal chromosome feature known as the “Philadelphia Chromosome” who have not received prior treatment. ALL patients with this abnormal chromosome are said to have “Philadelphia chromosome positive ALL,” which is abbreviated as Ph+ ALL.

The purpose of this study is to determine how well Ph+ ALL responds to treatment with the drug dasatinib. Dasatinib will be given along with standard chemotherapy and transplantation treatments for Ph+ ALL.

Dasatinib blocks the action of the abnormal chromosome feature, and it inhibits the growth of leukemia cells. Dasatinib has been FDA approved for patients with chronic myeloid leukemia that has the Ph+ chromosome and in Ph+ ALL patients who have not responded to treatment. However, the use of dasatinib in patients newly diagnosed with Ph+ ALL is experimental.

Once enrolling in the study, patients will receive a series of monthly treatments for leukemia which may include autologous transplantation. The length of time receiving treatment in this study will depend on your response to the therapy.



Key Eligibility

  • Men and women age 50 and older
  • Diagnosed a clinical trial for patients with acute lymphoblastic leukemia (ALL)
  • No prior therapy
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Ellen Ritchie, MD


Protocol ID

CALGB 10701

Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page